A novel syphilis Treponema pallidum lipoprotein peptide antigen diagnostic assay using red cell kodecytes in routine blood centre column agglutination testing platforms
Vox Sanguinis · 2024
DOI: 10.1111/vox.13628 ↗Kurz gefasst
Fachartikel in der Zeitschrift Vox Sanguinis, 2024. Verfasst von Suvro Sankha Datta und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Transfusion Medicine, Tata Medical Center, Kolkata, India. Hauptthemen laut MEDLINE: Treponema pallidum, Syphilis, Lipoproteins, Antigens, Bacterial. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 24 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Background and Objectives The detection of treponemal antibodies, which are used to make a diagnosis of syphilis, is important both for diagnostic purposes and as a mandatory blood donor test in most countries. We evaluated the feasibility of using Kode Technology to make syphilis peptide red cell kodecytes for use in column agglutination serologic platforms. Materials and Methods Candidate Kode Technology function‐spacer‐lipid (FSL) constructs were made for the Treponema pallidum lipoprotein (TmpA) of T. pallidum , using the peptide and FSL selection algorithms, and then used to make kodecytes. Developmental kodecytes were evaluated against a large range of syphilis antibody reactive and non‐reactive samples in column agglutination platforms and compared against established methodologies. Overall, 150 reactive and 2072 non‐reactive Syphicheck assay (a modified T. pallidum particle agglutination) blood donor samples were used to evaluate the agreement rate of the developed kodecyte assay.
Results
From three FSL‐peptide candidate constructs, one was found to be the most suitable for diagnostics. Of 150 Syphicheck assay reactive samples, 146 were TmpA–kodecyte reactive (97.3% agreement), compared with 58.0% with the rapid plasmin reagin (RPR) assay for the same samples. Against the 2072 expected syphilis non‐reactive samples the agreement rate for TmpA–kodecytes was 98.8%.
Conclusion
TmpA–kodecytes are viable for use as cost‐effective serologic reagent red cells for the detection of treponemal antibodies to diagnose syphilis with a high level of specificity in blood centres. This kodecyte methodology also potentially allows for introduction of the reverse‐algorithm testing into low‐volume laboratories, by utilizing existing transfusion laboratory infrastructure.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Transfusion Medicine, Tata Medical Center, Kolkata, India.
- Department of Pathology and Laboratory Medicine, Auckland City Hospital, Auckland, New Zealand.
- Kode Technology Laboratory, School of Engineering, Computer and Mathematical Sciences, Faculty of Design and Creative Technologies, Auckland University of Technology, Auckland, New Zealand.
- Kode Biotech Limited, Auckland, New Zealand.
ORCID-Profile: Suvro Sankha Datta
Zitieren
APA
Datta, S. S., Nagappan, R., Biswas, D., Basu, D., Gupta, K., Mondal, P. K., Tuzikov, A., Bovin, N. V., & Henry, S. M. (2024). A novel syphilis Treponema pallidum lipoprotein peptide antigen diagnostic assay using red cell kodecytes in routine blood centre column agglutination testing platforms. Vox Sanguinis. https://doi.org/10.1111/vox.13628
Vancouver
Datta SS, Nagappan R, Biswas D, Basu D, Gupta K, Mondal PK, et al. A novel syphilis Treponema pallidum lipoprotein peptide antigen diagnostic assay using red cell kodecytes in routine blood centre column agglutination testing platforms. Vox Sanguinis. 2024. doi:10.1111/vox.13628
BibTeX
@article{Datta2024,
author = {Datta, Suvro Sankha and Nagappan, Radhika and Biswas, Durba and Basu, Debapriya and Gupta, Kaushik and Mondal, Pradip Kumar and Tuzikov, Alexander and Bovin, Nicolai V and Henry, Stephen M},
title = {A novel syphilis Treponema pallidum lipoprotein peptide antigen diagnostic assay using red cell kodecytes in routine blood centre column agglutination testing platforms},
journal = {Vox Sanguinis},
year = {2024},
doi = {10.1111/vox.13628}
}
EUVIMED